Biocon Ltd has inked a semi-exclusive distribution and supply deal with Mexico-based Medix for the commercialization of Liraglutide (gSaxenda), a drug used in chronic weight management. The agreement tasks Biocon with obtaining regulatory approval, manufacturing, and supplying the drug, while Medix will handle its commercialization in Mexico. Biocon’s CEO Siddharth Mittal emphasized the collaboration’s goal to provide affordable access to the drug for obesity patients in Mexico. Medix, with over 70 years of experience in addressing obesity, aims to improve the quality of life for Mexico’s population, where 70% suffer from obesity.